Patents by Inventor Isabelle Lyothier

Isabelle Lyothier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11839613
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: December 12, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11712438
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 1, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20230165859
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: November 27, 2022
    Publication date: June 1, 2023
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Patent number: 11446298
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 20, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20220175775
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 9, 2022
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Patent number: 11325899
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 10, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • Publication number: 20210115031
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20210113559
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200289507
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 17, 2020
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Publication number: 20200179383
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: June 11, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200108068
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200069686
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Publication number: 20110212950
    Abstract: The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R2, has the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: October 24, 2008
    Publication date: September 1, 2011
    Applicant: NOVARTIS AG
    Inventors: Dirk Behnke, Peter Herold, Stjepan Jelakovic, Nathalie Jotterand, Isabelle Lyothier, Robert Mah, Stefan Stutz, Vincenzo Tschinke
  • Patent number: 7723550
    Abstract: Process for preparing a compound of the formula (I) in which R1 and R2 are each independently H, C1-C8-alkyl, halogen, polyhalo-C1-C8-alkoxy, polyhalo-C1-C8-alkyl, C1-C8-alkoxy, C1-C8-alkoxy-C1-C8-alkyl, or C1-C8-alkoxy-C1-C8-alkoxy, where R1 and R2 are not both H, and R3 is C1-C8-alkyl, which is characterized in that a) a compound of the formula (II) in which R1 and R2 are each as defined above and X is Br, I, triflate, toyslate or mesylate is reacted with prop-2-yn-1-ol to give the compound of the formula (III), b) the compound of the formula (III) is reacted with an alkyl-metal compound in which “alkyl” is as defined above for R3 to give a compound of the formula (I).
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: May 25, 2010
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Stefan Stutz, Aleksandar Stojanovic, Isabelle Lyothier, Dirk Behnke
  • Publication number: 20090325947
    Abstract: The application relates to novel nitrate ester derivatives of substituted piperidines of the general formula (I), wherein R1, R2, R3, X, Y and Z0, and m, n, p and q have the meanings explained in more detail in the description, a process for their preparation and the use of these compounds as a curative agent in cardiovascular diseases, in particular in high blood pressure and vascular and organ damage accompanying high blood pressure.
    Type: Application
    Filed: August 7, 2007
    Publication date: December 31, 2009
    Inventors: Peter Herold, Robert Mah, Stefan Stutz, Vincenzo Tschinke, Isabelle Lyothier, Christoph Schumacher, Christiane Marti, Nathalie Jotterand
  • Publication number: 20090306062
    Abstract: The application relates to 2,5-disubstituted piperidines, their preparation and use as medicines, especially as renin inhibitors, of the general formula (I) in which R, R1 and X are each as defined in detail in the description, and pharmaceutical preparations comprising these compounds.
    Type: Application
    Filed: June 7, 2007
    Publication date: December 10, 2009
    Inventors: Peter Herold, Robert Mah, Stefan Stutz, Vincenzo Tschinke, Isabelle Lyothier, Stjepan Jelakovic, Michael Quirmbach, Christiane Marti
  • Publication number: 20090105503
    Abstract: Process for preparing a compound of the formula (I) in which R1 and R2 are each independently H, C1-C8-alkyl, halogen, polyhalo-C1-C8-alkoxy, polyhalo-C1-C8-alkyl, C1-C8-alkoxy, C1-C8-alkoxy-C1-C8-alkyl, or C1-C8-alkoxy-C1-C8-alkoxy, where R1 and R2 are not both H, and R3 is C1-C8-alkyl, which is characterized in that a) a compound of the formula (II) in which R1 and R2 are each as defined above and X is Br, I, triflate, toyslate or mesylate is reacted with prop-2-yn-1-ol to give the compound of the formula (III), b) the compound of the formula (III) is reacted with an alkyl-metal compound in which “alkyl” is as defined above for R3 to give a compound of the formula (I).
    Type: Application
    Filed: November 8, 2007
    Publication date: April 23, 2009
    Inventors: Peter Herold, Robert Mah, Stefan Stutz, Aleksandar Stojanovic, Isabelle Lyothier, Dirk Behnke
  • Publication number: 20090088576
    Abstract: A process for the synthesis of an alcohol of formula (I), using as intermediate a compound of formula (V).
    Type: Application
    Filed: January 29, 2007
    Publication date: April 2, 2009
    Inventors: Peter Herold, Stefan Stutz, Robert Mah, Aleksandar Stojanovic, Isabelle Lyothier, Dirk Behnke, Felix Spindler, Erhard Bappert